Myricx Pharma Ltd Revenue and Competitors

Stevenage,

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Myricx Pharma Ltd's estimated annual revenue is currently $1.2M per year.(i)
  • Myricx Pharma Ltd's estimated revenue per employee is $77,500

Employee Data

  • Myricx Pharma Ltd has 15 Employees.(i)
  • Myricx Pharma Ltd grew their employee count by 15% last year.

Myricx Pharma Ltd's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Clinical DevelopmentReveal Email/Phone
3
Head BioinformaticsReveal Email/Phone
4
Chief Scientific Officer and Co-founderReveal Email/Phone
5
Chief Financial OfficerReveal Email/Phone
6
ChairmanReveal Email/Phone
7
Chemistry Consultant and Co-founderReveal Email/Phone
8
Senior Research ScientistReveal Email/Phone
9
Senior Research ScientistReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$81.4M37540%N/AN/A
#2
$16.9M10922%N/AN/A
#3
$156.1M120-70%$145MN/A
#4
$2.9M37-24%$150MN/A
#5
$1.3M170%$459.5MN/A
#6
$49.2M25415%$180.7MN/A
#7
$7M45-2%N/AN/A
#8
$256.3M8409%$168.5MN/A
#9
$4.2M27-7%N/AN/A
#10
$10.1M655%N/AN/A
Add Company

What Is Myricx Pharma Ltd?

We are a drug discovery company selectively targeting protein myristoylation for the treatment of cancer and viral diseases

keywords:N/A

N/A

Total Funding

15

Number of Employees

$1.2M

Revenue (est)

15%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Myricx Pharma Ltd News

2020-11-16 - Myricx Pharma : Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer

Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brando ...

2020-11-16 - Myricx Pharma Raises £4.5M in Seed Financing

Myricx Pharma, a Stevenage, United Kingdom-based drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, raised £4.5m in seed financing. Backers included Sofinnova Partners and Brandon Capital Partners. T ...

2020-11-16 - Myricx Pharma : Launches with £4.5M Financing to Progress its Novel NMT inhibitors in Cancer

Myricx Pharma (‘Myricx’), a drug discovery company focused on developing small molecule inhibitors that selectively target the human N-myristoyltransferases (NMT) in cancer, today unveiled an initial £4.5 million in seed financing from experienced venture investors, Sofinnova Partners and Brando ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$1.3M150%N/A
#2
$2.3M23N/AN/A
#3
$4.3M23-8%N/A
#4
$5.3M280%N/A
#5
$3.6M313%N/A